Oncostatin M in Ulcerative Colitis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2024-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease

NCT06959654

Ulcerative Colitis Disease Patients and Normal Patients

NOT_YET_RECRUITING NA

Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis

NCT02922374

Acute Severe Colitis (ASC)

UNKNOWN PHASE1/PHASE2

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

NCT05907330

Ulcerative Colitis

NOT_YET_RECRUITING PHASE2

MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.

NCT04272307

Inflammatory Bowel Diseases Colitis Ulcerative

UNKNOWN

The Role of Intestinal Ultrasound in Monitoring the Response to Biological Therapy in Patients With Ulcerative Colitis

NCT05606939

Ulcerative Colitis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications.

Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulcerative colitis Patients

45 Patients with UC. The diagnosis of UC will be based on endoscopic finding and histopathological finding

Group Type ACTIVE_COMPARATOR

Oncostatin M

Intervention Type DIAGNOSTIC_TEST

Test to diagnosis of Ulcerative colitis

Control

45 apparently healthy subjects as controls who were not UC

Group Type ACTIVE_COMPARATOR

Oncostatin M

Intervention Type DIAGNOSTIC_TEST

Test to diagnosis of Ulcerative colitis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oncostatin M

Test to diagnosis of Ulcerative colitis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients aged \>18 years and \<80 years, of both gender who diagnosed to have UC and given the consent for participation in the study

Exclusion Criteria

* 1- Any patient with systemic inflammation as Bronchial asthma. 2- History of cancer or tumor. 3- Autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes